S6196

Simvastatin

≥97% (HPLC), solid

• 동의어(들): MK-733, SVA
• 실험식(Hill 표기법): C₂₅H₃₈O₅
• CAS Number: 79902-63-9
• Molecular Weight: 418.57
• MDL number: MFCD00072007
• UNSPSC 코드: 12352200
• PubChem Substance ID: 24724617
• NACRES: NA.77

속성

• 분석: ≥97% (HPLC)
• 형태: solid
• 색상: white
• mp: 127-132 °C (lit.)
• solubility: DMSO: ≥20 mg/mL
• 주관자: Merck & Co., Inc., Kenilworth, NJ, U.S.
• 저장 온도: 2-8°C
• SMILES string: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC
• InChI: 1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
• InChI key: RYMZZMVNJRMUDD-HGQWONQESA-N
• 유전자 정보: human ... HMGCR(3156) ; rat ... Hmgcr(25675)

설명

일반 설명

Simvastatin is a prodrug. Simvastatin is a semisynthetic derivative/analog of lovastatin. Simvastatin is insoluble in water but is soluble in polar organic solvents.

애플리케이션

Simvastatin has been used:

• as an inhibitor of HMG CoA reductase (HMGCR)
• to study its effects on epithelial to mesenchymal transition (EMT) and the prognosis of patients with lung adenocarcinoma
• in in vivo studies to test its effect on brain tumor−initiating cells (BTIC) viability and cell proliferation
• to study the role of adenosine triphosphate (ATP)-binding cassette transporter A7 in phagocytosis of Jurkat cells
• to study the effect on endothelial dysfunction and inflammation in mice

생화학적/생리학적 작용

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins cholesterol and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid and can be activated prior to use with NaOH in EtOH treatment. It may also have beneficial effects on endothelial function, inflammation, smooth muscle cell function, vascular wall function, hemostasis and LDL oxidation.

특징 및 장점

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS08
• 신호어: Warning
• 유해 및 위험 성명서: H361d
• 예방조치 성명서: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Repr. 2
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable
• 개인 보호 장비: Eyeshields, Gloves, type N95 (US)